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Abstract
The lymphatic vascular system functions to maintain fluid homeostasis by removing fluid from the
interstitial space and returning it to venous circulation. This process is dependent upon the
maintenance and modulation of a semi-permeable barrier between lymphatic endothelial cells of the
lymphatic capillaries. However, our understanding of the lymphatic endothelial barrier and the
molecular mechanisms that govern its function remains limited. Adrenomedullin (AM) is a 52 amino
acid secreted peptide which has a wide range of effects on cardiovascular physiology and is required
for the normal development of the lymphatic vascular system. Here, we report that AM can also
modulate lymphatic permeability in cultured dermal microlymphatic endothelial cells (HMVEC-
dLy). AM stimulation caused a reorganization of the tight junction protein ZO-1 and the adherens
protein VE-cadherin at the plasma membrane, effectively tightening the endothelial barrier.
Stabilization of the lymphatic endothelial barrier by AM occurred independently of changes in
junctional protein gene expression and AM−/− endothelial cells showed no differences in the gene
expression of junctional proteins compared to wildtype endothelial cells. Nevertheless, local
administration of AM in the mouse tail decreased the rate of lymph uptake from the interstitial space
into the lymphatic capillaries. Together, these data reveal a previously unrecognized role for AM in
controlling lymphatic endothelial permeability and lymphatic flow through reorganization of
junctional proteins.
Keywords
Adrenomedullin; VEGFA; Permeability; Lymphatic; Endothelial; Lymphography
1. Introduction
1.1
The lymphatic vascular system is a blind-ended network of endothelial cell lined vessels that
functions to maintain fluid homeostasis by unidirectionally transporting tissue fluid,
extravasated plasma proteins, lipids, and cells from the interstitium to the circulatory system
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by way of the thoracic duct. When the lymphatic vascular system fails to function properly
patients are at risk of developing serious and debilitating lymphedema. Pressure sensing,
fibrillin-rich anchoring filaments that tether lymphatic endothelial cells (LECs) to the
extracellular matrix contract in response to increases in interstitial pressure, thereby stretching
LECs apart and facilitating lymph uptake into lymphatic capillaries. However, recent evidence
suggests that LECs are also active participants in lymph transport through formation of an
endothelial barrier that can regulate both ion and protein transport [3,7,19]. While these studies
have implicated vascular endothelial growth factors A and C (VEGFA, VEGFC) and the
intracellular signaling molecule cAMP as potential players in LEC permeability regulation,
there remains a need to identify pharmacologically tractable targets that can efficiently
modulate lymphatic permeability.
Adrenomedullin (AM) is a highly conserved 52 amino acid peptide vasodilator that is
upregulated in a variety of cardiovascular conditions [12,13,23]. First recognized for its ability
to maintain vascular smooth muscle tone, AM is also an important regulator of endothelial cell
biology. For example, numerous in vitro studies have shown that AM is a potent angiogenic
factor [10,20,32]. Our own recent studies using knockout mice have revealed that AM and its
receptors are required for normal lymphatic vascular development [11].
With regard to endothelial permeability, AM treatment of human umbilical vein endothelial
cell (HUVEC) monolayers dose dependently reduced hyperpermeability caused by
inflammatory mediators including H2O2, thrombin, E. coli hemolysin and S. aureus α-toxin
[2,14,16] The protective effect of AM on the endothelial barrier has also been shown in vivo
in rat ileum exposed to S. aureus α-toxin and ex vivo in rabbit lungs exposed to H2O2 [2,14].
Further, in the blood-brain barrier, several studies have shown that AM treatment increased
transendothelial electrical resistance thereby reducing endothelial permeability [18,21,22].
Taken together, these data suggest AM functions as a potent factor in maintaining the blood
endothelial barrier; however, whether this function is conserved in LECs and to what extent
remains unknown.
The purpose of this study was to explore the role of AM in the regulation of lymphatic
permeability. We evaluated the effects of AM on the expression and localization of LEC
junction components. Specifically, the response to AM treatment of the tight junction
molecules Zonulus Occludin (ZO-1), Claudin-5, Claudin-12, and Junction Adhesion
Molecular C (JAMC) as well as the endothelial-specific adherens protein VE-cadherin were
assessed. Further, the ability of AM to modulate LEC permeability was measured utilizing
both in vitro and in vivo approaches. The in vivo studies exploited the technique of fluorescent
tail microlymphography and provided functional validation of our in vitro observations.
Together, these data establish a previously unrecognized role of AM in stabilizing of the
endothelial barrier and modulating lymphatic flow in vivo.
2. Materials and Methods
2.1. Cell Culture
Cryopreserved adult human dermal lymphatic microvascular endothelial cells (HMVEC-dLys)
were obtained from Cambrex (Walkersville, MD) and maintained in Clonetics (East
Rutherford, NJ) microvascular endothelial growth medium (EGM-2MV) and endothelial basal
medium (EBM), respectively. Human AM and human AM 22–52 were purchased from
American Peptide (Sunnyvale, CA), Forskolin from Sigma-Aldrich, and recombinant human
VEGFA from Pierce Biotechnology. Goat anti-VE-cadherin (C-19) antibody was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti- ZO-1 antibody (33–9100) was
obtained from Zymed (San Francisco, CA). Cy2 and Cy3-labeled secondary antibodies were
from Jackson Immunoresearch (West Grove, PA).
Dunworth et al. Page 2













2.2 Immunofluorescence labeling and microscopy
For ZO-1 and VE-cadherin localization, cells were grown on 0.2% gelatin coated coverslips
until they achieved confluence. The medium was changed to serum-free conditions and the
cells were stimulated with AM (100 nM), VEGFA (10 ng/mL) or vehicle (0.1% BSA) for 30
min. The cells were then washed twice with PBS with calcium and then fixed/permeabilized
in ice-cold ethanol for 30 min. Cells were blocked with 3% BSA in PBS for 1 h at RT and
incubated with primary antibody in 3% BSA overnight at 4°C and with appropriate secondary
antibody for 1 h at RT. Nuclei were labeled with Hoechst 33258 (Sigma). The coverslips were
mounted on glass slides and images were obtained with a Nikon E800 microscope with a
Hammamatsu ORCA-ER CCD camera using Metamorph Software (Molecular Devices) and
processed in Adobe Photoshop 8.0 (Adobe).
2.3. Endothelial cell permeability
HMVEC-dLys permeability was studied as previously described [6,24,27]. Briefly, cells were
plated at a density of 1 × 105 cells/cm2 on gelatin-coated membranes (Corning Costar
Transwells, 0.4 µm pore size, 6.5 mm diameter) and medium was changed every 24 h.
Permeability of monolayers was measured in terms of Trypan Blue-BSA (TB-BSA) transfer
[27]. At 96 h post seeding, membranes were incubated with test ligands in HBSS containing
0.03 M HEPES (HBSS/HEPES) in both the apical and basal-lateral chambers. In the apical
chamber, 4% TB-BSA was added with or without test ligands followed by gentle shaking at
37°C/5% CO2 under sterile conditions for 90 min. At the end of the incubation, samples were
taken from the lower chamber and the absorbance at 590nm was measured. The relative
permeability was calculated by dividing the OD of treated samples by vehicle control.
2.4. Gene Expression Analysis
Total RNA was isolated from cells using the Qiagen RNAEasy Mini Kit and DNase Treated
with Promega DNase per manufactures instructions. RNA was reverse transcribed using MMV
reverse transcriptase (Invitrogen). cDNA was used for semi-quantitative RT-PCR or
quantitative RT-PCR using gene-specific primers, SYBR Green (Stratagene), and the
Stratagene MXP3000 and MxPro Software (Stratagene). The following murine primers
sequences were used: VE-Cadherin: Forward: 5’-GGTGGCCAAAGACCCTGAC-3’
Reverse: 5’-ACTGGTCTTGCGGATGGAGT-3’, JAMC: Forward: 5’-
GCTGGGAGAGCACATGCAA-3’ Reverse: 5’-CAGGAGCTCTGGGCTCACA-3’. Primers
sequences for ZO-1, Claudin-5 and Claudin-12 were designed by the report by Holmes et al.
[17]. The following human primers sequences were used: VE-Cadherin: Forward: 5’-
GCCAGGTATGAGATCGTGGT-3’ Reverse: 5’-GTGTCTTCAGGCACGACAAA-3.
Primer sets for human ZO-1, Claudin-5, Claudin-12, and JAMC were purchased from Qiagen.
2.5. Isolation of AM−/− Endothelial Cells
The generation and characterization of mice with targeted deletion of the Adm gene has been
previously described [4]. To isolate AM−/− endothelial cells, timed matings were established
between AM+/− mice and embryos were harvested at embryonic day 13.5. Genotyping was
performed as previously described [4] on genomic DNA isolated from yolk sacs. Whole
embryos were treated with enzyme solution containing 2.4U/mL Neutral Protease and 150U/
mL Collagenase Type II (Worthington Biochemical) at 37°C for 30 minutes to generate a single
cell suspension. Cells were incubated with 3 µg Rat anti-Mouse CD31 (BD Pharmigen) at 4°
C for 30 minutes and then washed 3 times. The cells were then incubated with Sheep anti-Rat
IgG Dynabeads (Invitrogen) at 4°C for 20 minutes and then washed 4 times. Bead-bound cells
were collected for RNA purification and levels of gene expression for junctional proteins were
determined as described above.
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2.6. Quantitative Tail Microlymphography
The flow velocity of the dermal lymphatic vessels in the mouse tail was measured as previously
described [25]. Briefly, adult male 129S6/SvEv mice were anesthetized by subcutaneous
injection of avertin at a concentration of 0.5mg/gm body weight. Mice placed on a heating pad
in the working space underneath a Leica MZ 16 FA dissecting microscope. The tail was
immobilized on the pad with two-sided tape. Next, 1 µL of a 25% FITC-Dextran (2,000,000
kDa) with vehicle or AM peptide [10 ng/μL] was loaded into a microsyringe (Hamilton, Reno,
NV) fitted with a 30-gauge needle and was injected intradermally at the tip of the mouse tail.
The flow of FITC-Dextran through the dermal lymphatics was acquired with a camera fitted
onto the Leica microscope every minute for 15 minutes. Flow rates were determined using
offline image analysis (Adobe Photoshop 8.0 and Image J) and application of a stepwise
polynomial equation [25]. The data for each subregion were fit to this equation with a least
squares nonlinear regression algorithm. All animal procedures were approved by the
Institutional Animal Care and Use Committee of the University of North Carolina at Chapel
Hill.
2.7. Statistics
Results are represented as +/− S.E.M. Statistical analyses were performed with a Student t test
with unequal variance. A P value of<.05 was considered statistically significant.
3. Results
3.1. AM prevents VEGFA-mediated increase in lymphatic endothelial cell permeability
HMVEC-dLys were grown to a monolayer in transwells and paracellular permeability was
measured by the ability of Trypan Blue-labeled bovine serum albumin (TB-BSA) to pass
through a monolayer from the apical chamber to the basal lateral chamber in the presence or
absence of AM or VEGFA [6]. Treatment with AM did not change the basal permeability of
the HMVEC-dLy monolayer compared to vehicle control (Figure 1). As expected, treatment
with VEGFA resulted in a significant increase in permeability across the HMVEC-dLys
monolayer. AM stimulation of LECs in the presence of VEGFA dose-dependently prevented
the VEGFA-induced increase in permeability of the HMVEC-dLys monolayer to albumin.
Therefore, although AM did not affect LEC permeability under basal conditions, it was highly
effective at counteracting the permeabilizing effects of VEGFA on cultured LECs.
3.2. AM stabilizes lymphatic endothelial cell-cell junctions
HMVEC-dLys were grown to confluence and then treated with vehicle control, AM, VEGFA,
or the combination of AM with VEGFA. Vehicle treated HMVEC-dLys displayed a mosaic
pattern of ZO-1 and VE-cadherin staining that was characterized by both continuous and
discontinuous patches along the cell-cell membranes (Figure 2A and 2D). Treatment of
HMVEC-dLys with AM resulted in the formation of continuous tight junction strands as
indicated by the tight junction protein ZO-1 (Figure 2B). Further, AM caused a reorganization
of VE-cadherin at the plasma membrane which appeared as a linearized adherence junction
band compared to vehicle treated cells (Figure 2F). As expected, treatment with VEGFA
dramatically disrupted of both ZO-1 and VE-cadherin localization, indicated by gaps and an
intermittent, zipper-like staining pattern (Figures 2C and 2G). Surprisingly, co-treatment of
AM with VEGFA completely abrogated the VEGFA induced disruption ZO-1 and VE-
cadherin localization at the plasma membrane (Figure 2D and 2H). We also noticed that AM
treatment appeared to only affect the localization of ZO-1 and VE-cadherin, but not the total
amount of protein present at the cellular junctions. These data demonstrate that AM functions
to reorganize LEC paracellular junctions by forming a tighter paracellular seal between cells
and preventing their disruption by permeabilizing agents such as VEGFA.
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3.3. AM stimulation does not change the expression of junction genes at the RNA level
RNA was isolated from LECs treated with AM or with vehicle control and gene expression
was measured by quantitative RT-PCR. There was no significant difference in the expression
of ZO-1, Claudin-5, Claudin-12, JAMC, or VE-cadherin between AM treated and vehicle
control (Figure 3). Therefore, the effects of AM on LEC junction composition are independent
of changes in gene expression, suggesting that modulation of lymphatic function by AM is
likely to occur rapidly in vivo.
3.4. Genetic depletion of AM does not change the expression of junction genes at the RNA
level
To determine whether a genetic reduction in AM could influence the expression of junction
genes in vivo, we isolated endothelial cells from AM−/− mice at embryonic day 13.5. Although
somewhat reduced, the gene expression levels of ZO-1, Claudin-5, Claudin-12, JAMC and
VE-cadherin were not statistically different in AM−/− endothelial cells compared to endothelial
cells isolated from wildtype littermate controls (Figure 4). Therefore, even though AM−/− mice
die at mid-gestation with vascular defects, the loss of AM in endothelial cells does not affect
the expression of genes important for endothelial barrier function.
3.5. AM reduces lymphatic flow in vivo
To address whether the permeability effect of AM on LECs could result in altered lymphatic
flow in vivo we used fluorescent tail microlymphography in adult male mice. Like in humans,
lymphography of the mouse tail provides a sensitive and quantitative measure of dermal
lymphatic capillary flow that is largely independent of the extrinsic effects of blood flow on
lymphatic function. Briefly, FITC-dextran in the presence or absence of AM was injected into
the interstitial space of the mouse tail, and the ability of the dextran to enter the lymphatic
capillaries was monitored over time. Consistent with previously published results from other
groups [1,25,31], the basal lymphatic flow rates in the wild-type SvEV129/6 mouse tail was
0.78 mm/min (Figure 5). When AM was co-administered with the FITC-dextran, we
consistently found a significant decrease in lymphatic flow rates, with an average uptake rate
of 0.52 mm/min. Therefore, these data demonstrate that AM can potently reduce lymphatic
flow rates in vivo.
4. Discussion
4.1
In the present study, we demonstrate that AM stabilizes the barrier function of LECs both in
vitro and in vivo. AM dose-dependently prevented VEGFA-mediated increases in permeability
of cultured HMVEC-dLys to albumin. Molecularly, AM treatment reorganized ZO-1 and VE-
cadherin at the plasma membrane to form continuous cell-cell contacts, thereby limiting
paracellular transport. In addition, we showed that exogenous AM peptide effectively slowed
lymphatic flow rates in the mouse tail. Importantly, the ability of AM to modulate lymphatic
barrier functions was independent of changes in gene expression of tight junction and adherens
junction components both in vitro and in a genetic knockout mouse model.
Previous studies have shown that AM can stabilize the endothelial barrier of various blood
vascular beds during inflammatory conditions (H2O2, thrombin, S. aureus α-toxin, E. coli.
Hemolysin) and thus presumably reduce edema formation [2,14,16,32]. However in another
study, AM increased inflammatory edema accumulation caused by substance P and bradykinin
[5]. Although these studies were not able to separate the direct anti-inflammatory functions of
AM from its effects on vascular permeability, our study sheds new light of the in vivo functions
of AM in vascular beds that contain both blood and lymphatic capillaries. We found that the
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ability of AM to maintain barrier function is not limited to blood endothelial cells but also
affects LECs. Because lymphatic uptake was significantly reduced after co-administration of
AM in vivo, our results suggest an essential role for AM in perpetuating inflammatory edema.
The VEGF family members VEGFA and VEGFC have both been shown to modulate lymphatic
permeability. Targeted overexpression of VEGFA in the mouse epidermis exacerbated
lymphatic leakage after acute UVB irradiation [19], while polymorphisms in the VEGFA
promoter region leading to enhanced VEGFA expression have been attributed to hydrocele
development in lymphatic filariasis [7]. In addition, VEGFC has been demonstrated to reduce
the transendothelial electrical resistance (TEER) of a LEC monolayer [3]. While both VEGFA
and VEGFC increase lymphatic permeability, AM represents one of the first angiogenic factors
that can stabilize the lymphatic endothelial barrier. Therefore, the local interactions between
VEGF family members and AM in regulating blood and lymphatic microcirculation warrant
additional investigation.
We have previously shown that AM and its receptors are essential for the development and
function of the lymphatic vasculature [11]. AM transduces its signal through a G-protein
coupled receptor, calcitonin receptor-like receptor (CLR) when the receptor is associated with
receptor activity modifying protein 2 (RAMP2) [26]. Mice that have targeted deletions of the
genes that encode for either AM, CLR, or RAMP2 die at mid-gestation with generalized edema
that is characterized by diminished proliferation of LECs [11]. A conditional knockout of CLR
in endothelial cells using the Cre-LoxP homologous recombination system also resulted in a
similar phenotype, supporting an essential function for AM signaling in endothelial cells
[11]. Our studies, and those of others [28,29], have shown that AM and its receptors are
intrinsically enriched in LECs compared to blood vascular endothelial cells. Therefore, the
enhanced sensitivity of LECs to local AM provides an explanation, in part, for the remarkable
phenotype of the null mice. Our current study extends our understanding of AM function in
LECs and suggests that an additional factor leading to the embryonic edema of the null mice
may be leaky, hyperpermeable lymphatic capillaries that are unable to support lymphatic flow
in vivo. Consistent with findings from other groups [22,32], the fact that isolated endothelial
cells lacking AM had normal expression of genes encoding junctional proteins further
demonstrates that the effects of AM on the endothelial cell barrier are largely mediated by
structural reorganization of the plasma membrane rather than changes in gene expression.
The unique molecular interface formed between the association of CLR with RAMPs provides
a distinctive target for pharmacological drug design. In fact, two compounds that target the
CLR-RAMP1 interface are currently in clinical trials for the treatment of migraine pain
associated with calcitonin gene related peptide biology [8,9,15,30]. Our current study suggests
that modulation of AM activity through small molecule targeting of the CLR-RAMP2 complex
could provide an effective means of altering lymphatic permeability for either the treatment of
lymphedema or the inhibition of tumor metastasis through the lymphatic vasculature.
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Effects of AM on the permeability of HMVEC-dLy monolayers. Cells were treated with 0.1%
BSA alone, AM (100 nM), VEGFA (10 ng/mL), or VEGFA with increasing concentrations of
AM (0.1 nM–100 nM) for 90 min. Relative changes in permeability were determined by
measuring TB-BSA transfer for each treatment normalized to vehicle. control. #P<0.01
compared to vehicle control. *P<0.01 compared to VEGFA treated. Data represented as mean
+/− SEM from 3 independent experiments, each performed in triplicate.
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AM stabilized the endothelial barrier in HMVEC-dLys in the presence of VEGFA. (A–B)
Treatment with 0.1% BSA (Veh.) showed intact monolayer as visualized by ZO-1 (A) and VE-
cadherin (B). (C–D) Stimulation with 100 nM AM resulted in linearization of both ZO-1 (C)
and VE-cadherin (D) at the cell-cell junction. (E–F) VEGFA (10 ng/mL) treated cells displayed
discontinued ZO-1 (E) and VE-cadherin staining (F). (G–H) Co-treatment of AM with VEGFA
stabilized ZO-1 (G) and VE-cadherin (H); completely preventing VEGFA-mediated barrier
disruption. Original magnification 400X. Each image is representative of each experimental
condition imaged from 4 separate fields repeated 3 times in triplicate.
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Stimulation of HMVEC-dLys with AM does not affect gene expression of junction
components. Total RNA was isolated from HMVEC-dLys treated with 0.1% BSA or 100 nM
AM and the gene expression of ZO-1, Claudin-5, Claudin-12, JAMC, and VE-cadherin were
assessed relative to GAPDH. No statistical significant differences were found between the two
groups suggesting the effect of AM on barrier function is independent to changes in gene
expression of junction components. n>3 with each assay performed in duplicate.
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Genetic loss of AM does not affect gene expression of junction components in vivo. Using
magnetic bead purification, endothelial cells were isolated from AM−/− and wildtype littermate
embryos at embryonic day 13.5. The gene expression of ZO-1, Claudin-5, Claudin-12,
JAMC, and VE-cadherin were determined and normalized to their expression in whole embryo.
Although AM−/− endothelial cells had somewhat diminished gene expression levels, there were
no statistically significant differences compared to wildtype endothelial cells. n>3 with each
assay performed in duplicate.
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AM decreases lymph uptake into the lymphatic capillaries in the mouse tail. Tails of SvEv129/6
wildtype mice were injected with 200 kDa FITC-Dextran and movement of the labeled-dye
into the lymphatic capillaries was measured over time. The rate of uptake in the absence of
AM was 0.78mm/min while the rate of uptake in the presence of AM was significantly
decreased to 0.52mm/min. P*<0.01. n>7 for each treatment group.
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